529P The management and outcome of crizotinib resistant patients: Comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI (Record no. 83674)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03224nab a2200277 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 190312b2019 xxu||||| |||| 00| 0 eng d |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Majumdar S |
| 245 ## - TITLE STATEMENT | |
| Title | 529P The management and outcome of crizotinib resistant patients: Comparison of patients who received ceritinib to those treated with chemotherapy or other oral TKI |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Date of publication, distribution, etc | 2018 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | |
| 500 ## - GENERAL NOTE | |
| General note | Abstract published in ESMO Asia Congress 23–25 November 2018, Singapore |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Background: Sequential use of ceritinib in crizotinib pretreated advanced ALK rearranged NSCLC is efficacious. Availability of ceritinib in resource constrained settings is limited.Sequential use of ceritinib in crizotinib pretreated advanced ALK rearranged NSCLC is efficacious. Availability of ceritinib in resource constrained settings is limited. Methods: Retrospective analysis of a prospective audit of all patients with advanced NSCLC (approved by Institutional Ethics Committee of Tata Memorial Hospital, registered with Clinical Trials Registry India, CTRI CTRI/2013/01/003335; all patients signed a written informed consent). All patients with ALK rearranged advanced NSCLC, who progressed on crizotinib were included. Data cutoff date was 17th July 2018. OS was calculated from the date of presentation to the hospital to date of death from any cause. Results: Between March 2013 and April 2018, there were 100 patients. 62% were male with a median age of 50 years (IQR 21-68). 87% were never smokers and 80% had no comorbidities. 37% had received crizotinib as first line therapy. 65% had a single site progression, most commonly brain (25.5%). Overall, 38 patients received ceritinib at some point during therapy. Ceritinib was used in second line in 58% patients, third line in 29% and in fourth line and beyond in 13%. Other therapy consisted of chemotherapy (5%), crizotinib with chemotherapy (39%), crizotinib continuation (18%), Alectinib (1%) and no therapy (9%). Median follow-up of surviving patients was 50 months (range: 1 to 62). Median PFS of the patients who received ceritinib was 5 months (95%CI, 3.4 to 6.6). Median OS of the entire cohort was 30 months (95%CI, 23.6 to 36.4). The median OS of the patients who received ceritinib was 32 months (95%CI, 26.3 to 37.7) versus 29 months (95%CI, 21-37) for other therapies, p = 0.41 by log rank test. Conclusions: In our cohort of patients with crizotinib resistant advanced NSCLC, there was no significant difference in OS and PFS between those who received ceritnib and those treated with chemotherapy/other TKI. In resource limited setting, chemotherapy or other TKI may be a practical alternative. Legal entity responsible for the study: Tata Memorial Hospital, Parel, Mumbai. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | chemotherapy regimen |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | protein-tyrosine kinase inhibitor |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | crizotinib |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | ceritinib |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Agarwal A |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noronha V |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Joshi A |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Patil V |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kumar R |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Prabhash K |
| 773 ## - HOST ITEM ENTRY | |
| Main entry heading | Annals of Oncology |
| Place, publisher, and date of publication | London : Oxford University Press,2018 |
| Relationship information | vol. 29., no s9. |
| International Standard Serial Number | 0923-7534 |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) | |
| Dept | Medical Oncology |
| Corporate name | TMC |
| Article Type | Conference Abstract |
| Country type | International |
| Added Entry | TMH |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Item type | Articles |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Permanent location | Current location | Date acquired | Barcode | Date last seen | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tata Memorial Hospital | Tata Memorial Hospital | 2019-03-12 | AR19336 | 2019-03-12 | Articles |